Current Editions
Drive-by analysis of accelerated approval is intellectual malpractice
Medical journals, news publications incorrectly conclude half of cancer accelerated approvals are useless
Editor's Commentary
Product Development
Rare disease spotlight: a leukodystrophy with small pipeline behind first approval
At least three MLD programs are coming up behind Orchard’s Lenmeldy, although three others were recently discontinued
Management Tracks
After years guiding Pfizer innovation initiative, Schoenbeck takes venture role at Canaan
In new role, the VC aims to combine elements of academic background with industry knowledge to create and develop new medicines
Protego names Warner CEO
Plus: Foghorn hires Humer and updates from Javelin, Stoke, Sensorium, Theradaptive and more
BioCentury ISSN 1097-7201